首页> 美国卫生研究院文献>other >Orthogonal Comparison of Molecular Signatures of Kidney Transplants with Subclinical and Clinical Acute Rejection – Equivalent Performance is Agnostic to either Technology or Platform
【2h】

Orthogonal Comparison of Molecular Signatures of Kidney Transplants with Subclinical and Clinical Acute Rejection – Equivalent Performance is Agnostic to either Technology or Platform

机译:具有亚临床和临床急性排斥反应的肾脏移植物分子特征的正交比较-等效性能对技术或平台均不可知

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We performed orthogonal technology comparisons of concurrent peripheral blood and biopsy tissue samples from 69 kidney transplant recipients, who underwent a comprehensive algorithm-driven clinical phenotyping. The sample cohort included patients with normal protocol biopsies and stable transplant function (TX, n=25), subclinical acute rejection (subAR, n=23), and clinical acute rejection (cAR, n=21). Comparisons between microarray and RNA sequencing (RNA-seq) signatures were performed, demonstrating a strong correlation between the blood and tissue compartments for both technology platforms. A number of shared differentially expressed genes and pathways between subAR and cAR in both platforms strongly suggest that these two clinical phenotypes form a continuum of alloimmune activation. SubAR is associated with fewer or less expressed genes than cAR in blood, whereas in biopsy tissues, this clinical phenotype demonstrates a more robust molecular signature for both platforms. The discovery work done in this study confirms a clear ability to detect gene expression profiles for TX, subAR and cAR in both blood and biopsy tissue, yielding equivalent predictive performance, that is agnostic to either technology or platform. Our data also provide strong biologic insights into the molecular mechanisms underlying these signatures, underscoring their logistical potential as molecular diagnostics to improve clinical outcomes following kidney transplantation.
机译:我们对来自69位肾移植受者的并发外周血和活检组织样本进行了正交技术比较,他们接受了综合算法驱动的临床表型分析。样本队列包括协议活检正常且移植功能稳定的患者(TX,n = 25),亚临床急性排斥反应(subAR,n = 23)和临床急性排斥反应(cAR,n = 21)。进行了微阵列和RNA测序(RNA-seq)签名之间的比较,证明了两种技术平台的血液和组织隔室之间都具有很强的相关性。在两个平台中,subAR和cAR之间的许多共享差异表达基因和途径都强烈表明,这两种临床表型形成了同种免疫激活的连续体。与血液中的cAR相比,SubAR与更少或更少的表达基因相关联,而在活检组织中,这种临床表型表明这两种平台都具有更强大的分子标记。在这项研究中完成的发现工作证实了在血液和活检组织中检测TX,subAR和cAR基因表达谱的明确能力,产生了与技术或平台无关的等效预测性能。我们的数据还为这些特征背后的分子机制提供了强大的生物学见解,突显了它们作为分子诊断技术的后勤潜力,可以改善肾脏移植后的临床结局。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号